Revenue
No reported data
MoonLake Immunotherapeutics (MLTX)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Research & development | $202.9M | $112.8M | $31.8M | $42.0M | — |
| Operating expenses | $244.8M | $143.1M | $54.1M | $65.1M | — |
| Operating income | −$244.8M | −$143.1M | −$54.1M | −$65.1M | −$4.6M |
| EBITDAderived | −$242.2M | −$141.7M | −$53.8M | −$64.9M | — |
| Net income | −$227.3M | −$118.9M | −$36.0M | −$50.0M | −$4.5M |
| Basic EPSper diluted share | -$3.53 | -$1.89 | -$0.73 | -$1.70 | -$0.31 |
| Diluted EPSper diluted share | -$3.53 | -$1.89 | -$0.73 | -$1.70 | -$0.31 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Bodenstedt MatthiasChief Financial Officer | SellClass A ordinary shares, par value $0.0001 per share | 39.1K | $22.04 | $862.2K | 1.12M |
| Jun 18, 2026Form 4 · 10b5-1 | Bodenstedt MatthiasChief Financial Officer | SellClass A ordinary shares, par value $0.0001 per share | 2.8K | $19.60 | $54.8K | 1.15M |
| Jun 17, 2026Form 4 · 10b5-1 | Bodenstedt MatthiasChief Financial Officer | SellClass A ordinary shares, par value $0.0001 per share | 15.1K | $19.68 | $296.8K | 1.16M |
| Jun 17, 2026Form 4 · 10b5-1 | Reich KristianChief Scientific Officer | SellClass A ordinary shares, par value $0.0001 per share · indirect | 50.0K | $19.43 | $971.5K | 2.82M |
| Jun 16, 2026Form 4 · 10b5-1 | Reich KristianChief Scientific Officer | SellClass A ordinary shares, par value $0.0001 per share · indirect | 50.0K | $18.70 | $935.0K | 2.87M |